Leibniz University of Hanover

About: Leibniz University of Hanover is a education organization based out in Hanover, Niedersachsen, Germany. It is known for research contribution in the topics: Finite element method & Computer science. The organization has 14283 authors who have published 29845 publications receiving 682152 citations.

Well-designed 3D ZnIn2S4 nanosheets/TiO2 nanobelts as direct Z-scheme photocatalysts for CO2 photoreduction into renewable hydrocarbon fuel with high efficiency

Abstract: A 3-dimensional (3D) ZnIn2S4/TiO2 Z-scheme system has been designed and constructed for photocatalytic reduction of CO2 into renewable hydrocarbon fuels without the use of a solid-state electron mediator. The unique 3D morphology, achieved by assembling 2D ZnIn2S4 nanosheets onto 1D TiO2 nanobelts, not only provides large surface area but also improves the separation and transfer efficiency of photogenerated electrons and holes. The 3D ZnIn2S4/TiO2 Z-scheme photocatalysts show excellent light-harvesting properties demonstrated in photocatalytic reduction of CO2, resulting in generation of desired hydrocarbons. The CH4 production rate of the 3D ZnIn2S4/TiO2 can reach up to 1.135 μmol g−1 h−1, which is about 39-times higher than that of bare ZnIn2S4 (0.029 μmol g−1 h−1). The enhanced photocatalytic activity is attributed to effective separation of the charge carriers between ZnIn2S4 and TiO2 through the direct Z-scheme instead of a type-II heterojunction. The photogenerated electrons in TiO2 nanobelts recombine with the holes in ZnIn2S4 nanosheets, and the unrecombined electrons/holes on different active sites have stronger reduction/oxidation abilities, leading to higher photocatalytic activity for CO2 reduction.

Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet

Abstract: This document updates the recommendations on the management of Philadelphia chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs) published in 2011 by the European LeukemiaNet (ELN) consortium. Recommendations were produced by multiple-step formalized procedures of group discussion. A critical appraisal of evidence by using Grades of Recommendation, Assessment, Development and Evaluation (GRADE) methodology was performed in the areas where at least one randomized clinical trial was published. Seven randomized controlled trials provided the evidence base; earlier phase trials also informed recommendation development. Key differences from the 2011 diagnostic recommendations included: lower threshold values for hemoglobin and hematocrit and bone marrow examination for diagnosis of polycythemia vera (PV), according to the revised WHO criteria; the search for complementary clonal markers, such as ASXL1, EZH2, IDH1/IDH2, and SRSF2 for the diagnosis of myelofibrosis (MF) in patients who test negative for JAK2V617, CALR or MPL driver mutations. Regarding key differences of therapy recommendations, both recombinant interferon alpha and the JAK1/JAK2 inhibitor ruxolitinib are recommended as second-line therapies for PV patients who are intolerant or have inadequate response to hydroxyurea. Ruxolitinib is recommended as first-line approach for MF-associated splenomegaly in patients with intermediate-2 or high-risk disease; in case of intermediate-1 disease, ruxolitinib is recommended in highly symptomatic splenomegaly. Allogeneic stem cell transplantation is recommended for transplant-eligible MF patients with high or intermediate-2 risk score. Allogeneic stem cell transplantation is also recommended for transplant-eligible MF patients with intermediate-1 risk score who present with either refractory, transfusion-dependent anemia, blasts in peripheral blood > 2%, adverse cytogenetics, or high-risk mutations. In these situations, the transplant procedure should be performed in a controlled setting.